LP 003 - Longbio Pharma
Alternative Names: LP-003 - Longbio PharmaLatest Information Update: 19 Apr 2024
At a glance
- Originator LongBio Pharma
- Class Antiallergics; Antiasthmatics; Antibodies; Skin disorder therapies
- Mechanism of Action IgE receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Allergic rhinitis; Asthma; Chronic urticaria
Most Recent Events
- 15 Apr 2024 LongBio Pharma announces intention to submit BLA in H1 2025
- 15 Apr 2024 LongBio Pharma plans a phase III trial in Q2 2024
- 08 Mar 2024 Updated efficacy and pharmacokinetic data from a phase I trial in Chronic urticaria presented at the American Academy of Dermatology annual Meeting (AAD-2024)